Featured Content

Winston Wong, PharmD
President, W-Squared Group

Febrile Neutropenia Pts Treated Quicker Under New Protocol

(Medscape Medical News) July 29, 2015 - Febrile neutropenia is an oncologic emergency that requires prompt treatment, but patients presenting to the emergency department (ED) often have to wait several hours before antibiotic therapy is initiated.

Commentary: Frankly, I have never thought of Febrile Neutropenia as a topic for a pathway, but it makes perfect sense. We...



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

Roche's Perjeta Regimen Approved In Europe For Use Before Surgery In Early Stage Aggressive Breast Cancer

(Roche) July 31, 2015 - The approval is based on the benefit seen with the Perjeta regimen in achieving pathological complete response (pCR) in the neoadjuvant (use before surgery) treatment of HER2-positive early breast cancer (eBC); this is the first approval in Europe based on pCR, a clinical endpoint that has allowed Perjeta to be made available to people with this aggressive disease faster.
read corporate press release »

Out-of-Pocket Costs More Stressful Than Cancer in Texas

(Medscape Medical News) July 31, 2015 - In a finding that points to the overwhelming impact of out-of-pocket expenses in American cancer care, more than 30% of patients with advanced cancer rated their financial distress to be more severe than their physical, family, and emotional distress, according to a new study from Texas.
read article (free registration required) »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



Febrile Neutropenia Pts Treated Quicker Under New Protocol (Medscape Medical News)

Frankly, I have never thought of Febrile Neutropenia as a topic for a pathway, but it makes perfect sense. We...posted by: Winston Wong, PharmD

Reining in the Total Cost of Cancer Care: It’s More Than Just Drugs (Yahoo! Finance)

While the statement of drug costs only being 40% of the total cost of oncology care may seem a bit low, especially...posted by: Winston Wong, PharmD

Osteoporosis Drug Could Benefit Postmenopausal Women with Breast Cancer (Cancer Research [UK])

Bisphosphonates have been approved for a long time for osteoporosis and for cancer that has metastasized to the...posted by: Debu Tripathy, MD

Foundation Medicine Initiates Multi-Center Clinical Study Evaluating Its Circulating Tumor DNA (ctDNA) Assay in Multiple Tumor Types (MarketWatch)

It's clear that serum-based testing of circulating free DNA or possibly circulating tumor cells is the next big...posted by: H. Jack West, MD

Top Oncologists Push Back on ‘Outrageous’ Costs of Cancer Drugs’ (KHN Morning Briefing)

The entire oncology community agrees that pricing of new drugs has become unsustainable. Thank you to all of those...posted by: Dean Gesme, MD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board

Ipsen has 1 new job posted.


Dava Oncology has 1 new job posted.


Bayer has 7 jobs posted.


Seattle Genetics has 3 jobs posted.


Check out the OBR Job Board here.





The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
MDVN +8.62%
PBYI +7.69%
BDSI +6.54%
CTIX -5.17%
SNSS -5.10%
MNKD -3.81%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: August 18, 2015
Company: Seattle Genetics, Inc.
Product: Adcetris® (brentuximab vedotin)

Date: August 27, 2015
Company: Bristol-Myers Squibb Co.
Product: Opdivo® (nivolumab)

Date: September 5, 2015
Company: Tesaro
Product: rolapitant

See All OBR Radar items»




OBR's Oncology Events Calendar is a compilation of important upcoming conferences and meetings that is updated daily.